Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 60 (RPL23AP60) is a processed pseudogene related to the ribosomal protein L23a gene (RPL23A). While the functional gene RPL23A encodes a component of the large (60S) ribosomal subunit involved in cytoplasmic protein synthesis, RPL23AP60 does not produce a functional protein and has no known biological function or disease association. Like other processed pseudogenes, it is a genomic remnant without coding potential, and there is no evidence it is a drug target or involved in human disease. It is one of many RPL23A pseudogenes identified in the human genome and is primarily used as a genomic marker in molecular genetics studies[1][3][5]. Key points: - This entry represents a pseudogene, not a protein-coding gene or therapeutic target. - There are no current biological functions, disease associations, or interacting drugs known for RPL23AP60. - Confusion may arise because the related functional protein (encoded by RPL23A) is a biologically important ribosomal subunit, but RPL23AP60 is not functional. If you are seeking information on the functional ribosomal protein, use Ribosomal protein L23a (RPL23A), not RPL23AP60[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 60 (RPL23AP60).